Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man
- PMID: 2280235
- DOI: 10.1111/j.1365-2796.1990.tb00283.x
Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man
Abstract
Plasma levels of neuropeptide Y-like immunoreactivity (NPY-LI) and noradrenaline were studied for 25 h in 22 patients with acute ischaemic heart disease. On admission, NPY-LI levels were above normal in 16 patients, and 20 patients had increased noradrenaline levels. The initial plasma NPY-LI did not differ between patients with acute myocardial infarction (AMI) and angina pectoris. Initial plasma noradrenaline levels were higher in patients with AMI than in those with angina pectoris. Plasma levels of noradrenaline remained elevated in AMI patients, but decreased towards normal values in patients with angina pectoris. Levels of NPY-LI returned to normal within 25 h in all patients. Tachycardia and left ventricular failure were related to high NPY-LI and noradrenaline levels. A positive correlation was found between noradrenaline and NPY-LI in plasma. It is suggested that neuropeptide Y (NPY), an endogenous vasoconstrictor peptide, should be considered as one of the mediators involved in the cardiovascular response to sympathetic activation induced by myocardial ischaemia.
Similar articles
-
Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction.Eur Heart J. 1994 Apr;15(4):454-61. doi: 10.1093/oxfordjournals.eurheartj.a060526. Eur Heart J. 1994. PMID: 8070470
-
Neuropeptide Y, noradrenaline and invasive haemodynamic data in mild to moderate chronic congestive heart failure.Clin Physiol. 1993 Jul;13(4):409-18. doi: 10.1111/j.1475-097x.1993.tb00340.x. Clin Physiol. 1993. PMID: 8370239
-
Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure.Cardiovasc Res. 1990 Feb;24(2):102-8. doi: 10.1093/cvr/24.2.102. Cardiovasc Res. 1990. PMID: 2328516
-
Bayliss Starling Prize Lecture 2023: Neuropeptide-Y being 'unsympathetic' to the broken hearted.J Physiol. 2025 Mar;603(7):1841-1864. doi: 10.1113/JP285370. Epub 2024 Jun 7. J Physiol. 2025. PMID: 38847435 Free PMC article. Review.
-
Autonomic control of the heart: going beyond the classical neurotransmitters.Exp Physiol. 2015 Apr 1;100(4):354-8. doi: 10.1113/expphysiol.2014.080184. Epub 2014 Nov 20. Exp Physiol. 2015. PMID: 25344273 Free PMC article. Review.
Cited by
-
Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors.Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):455-61. doi: 10.1007/s00210-004-0930-9. Epub 2004 Apr 22. Naunyn Schmiedebergs Arch Pharmacol. 2004. PMID: 15103451
-
Regulation of neuropeptide Y in body microenvironments and its potential application in therapies: a review.Cell Biosci. 2021 Aug 3;11(1):151. doi: 10.1186/s13578-021-00657-7. Cell Biosci. 2021. PMID: 34344469 Free PMC article. Review.
-
Levels of plasma neuropeptide Y and other vasoactive substances during head-up tilt in normal and essential hypertensive subjects.Clin Auton Res. 1995 Apr;5(2):67-70. doi: 10.1007/BF01827465. Clin Auton Res. 1995. PMID: 7620295 Clinical Trial.
-
Is neuropeptide Y co-released with catecholamines in experimental arterial hypertension following sinoaortic denervation?Naunyn Schmiedebergs Arch Pharmacol. 1992 Apr;345(4):431-6. doi: 10.1007/BF00176621. Naunyn Schmiedebergs Arch Pharmacol. 1992. PMID: 1620243
-
Changes in plasma catecholamine and neuropeptide Y levels after sympathetic activation in dogs.Br J Pharmacol. 1992 Jan;105(1):181-3. doi: 10.1111/j.1476-5381.1992.tb14232.x. Br J Pharmacol. 1992. PMID: 1596679 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous